source
- K2 Therapeutics seeks to blend China’s speed with global expertise after winning Endpoints 2026 awardK2 Therapeutics, a small drug development company, was named the winner of the Endpoints 2026 award. The company said it will try to combine the rapid development pace found in China with its own…
- Alnylam alumni lead RNAi biotech City Therapeutics to IPO filingBiotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...Endpoints · 25d ago↗ source
- Eli Lilly partners with China’s InnoCare on drug development deal worth up to $3.35 billion